Evolus Inc. (EOLS)
NASDAQ: EOLS
· Real-Time Price · USD
9.93
0.00 (0.00%)
At close: Jun 16, 2025, 3:59 PM
10.01
0.80%
After-hours: Jun 16, 2025, 07:26 PM EDT
Company Description
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States.
It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Evolus Inc.

Country | United States |
IPO Date | Feb 8, 2018 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 372 |
CEO | David Moatazedi |
Contact Details
Address: 520 Newport Center Drive Newport Beach, California United States | |
Website | https://www.evolus.com |
Stock Details
Ticker Symbol | EOLS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001570562 |
CUSIP Number | 30052C107 |
ISIN Number | US30052C1071 |
Employer ID | 46-1385614 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
David Moatazedi | President, Chief Executive Officer & Director |
Sandra Beaver | Chief Financial Officer |
Tomoko Yamagishi-Dressler | Chief Marketing Officer |
Dr. Rui Avelar C.CFP, Dip.SportMed, M.D. | Chief Medical Officer and Head of Research & Development |
Jeffrey J. Plumer | General Counsel |
Jessica Novak | Senior Vice President of Human Resources |
Kurt Knab | Senior Vice President of Sales |
Nareg Sagherian | Head of Global Investor Relations & Corporate Communications |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 16, 2025 | 4 | Filing |
Jun 10, 2025 | 4 | Filing |
Jun 06, 2025 | 8-K | Current Report |
May 27, 2025 | 8-K | Current Report |
May 15, 2025 | SCHEDULE 13G | Filing |
May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
May 14, 2025 | 4 | Filing |
May 14, 2025 | 4 | Filing |
May 14, 2025 | 4 | Filing |